{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:26:58Z","timestamp":1794860818616,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI68635"],"award-info":[{"award-number":["UM1 AI68635"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R37AI054165"],"award-info":[{"award-number":["R37AI054165"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI68635"],"award-info":[{"award-number":["UM1 AI68635"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI68614"],"award-info":[{"award-number":["UM1 AI68614"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI148450"],"award-info":[{"award-number":["UM1 AI148450"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the U.S., Chile, and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% neutralizing antibody titer (nAb ID50) measured four weeks after two doses were assessed as correlates of risk and protection against PCR-confirmed symptomatic SARS-CoV-2 infection (COVID-19). These analyses of SARS-CoV-2 negative participants were based on case-cohort sampling of vaccine recipients (33 COVID-19 cases by 4\u2009months post dose two, 463 non-cases). The adjusted hazard ratio of COVID-19 was 0.32 (95% CI: 0.14, 0.76) per 10-fold increase in spike IgG concentration and 0.28 (0.10, 0.77) per 10-fold increase in nAb ID50 titer. At nAb ID50 below the limit of detection (&lt; 2.612 IU50\/ml), 10, 100, and 270 IU50\/ml, vaccine efficacy was \u22125.8% (\u2212651%, 75.6%), 64.9% (56.4%, 86.9%), 90.0% (55.8%, 97.6%) and 94.2% (69.4%, 99.1%). These findings provide further evidence towards defining an immune marker correlate of protection to help guide regulatory\/approval decisions for COVID-19 vaccines.<\/jats:p>","DOI":"10.1038\/s41541-023-00630-0","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T23:35:40Z","timestamp":1678491340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine"],"prefix":"10.1038","volume":"8","author":[{"given":"David","family":"Benkeser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyi","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly E.","family":"Janes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Sproule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0588-8681","authenticated-orcid":false,"given":"Ann Marie","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Maaske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonya","family":"Villafana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Houchens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Jayashankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Castellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos J.","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Leith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanne","family":"Haugaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavesh","family":"Borate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars W. P.","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7127-2789","authenticated-orcid":false,"given":"Nima S.","family":"Hejazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0333-5925","authenticated-orcid":false,"given":"Lindsay N.","family":"Carpp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2652-3734","authenticated-orcid":false,"given":"April K.","family":"Randhawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele P.","family":"Andrasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1279-3741","authenticated-orcid":false,"given":"James G.","family":"Kublin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret Brewinski","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamodikoe","family":"Makhene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3949-9649","authenticated-orcid":false,"given":"Merlin L.","family":"Robb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2179-2436","authenticated-orcid":false,"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Neuzil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Follmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann R.","family":"Falsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Sobieszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Koup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6137-8312","authenticated-orcid":false,"given":"Ruben O.","family":"Donis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2662-9427","authenticated-orcid":false,"given":"Peter B.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the AstraZeneca AZD1222 Clinical Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Immune Assays Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the United States Government (USG)\/CoVPN Biostatistics Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"630_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 396, 467\u201378. (2020).","journal-title":"Lancet"},{"key":"630_CR2","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881\u201391. (2021).","journal-title":"Lancet"},{"key":"630_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111 (2021).","journal-title":"Lancet"},{"key":"630_CR4","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","volume":"397","author":"KRW Emary","year":"2021","unstructured":"Emary, K. R. W. et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet 397, 1351\u201362. (2021).","journal-title":"Lancet"},{"key":"630_CR5","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","volume":"385","author":"AR Falsey","year":"2021","unstructured":"Falsey, A. R. et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N. Engl. J. Med. 385, 2348\u201360. (2021).","journal-title":"N. Engl. J. Med."},{"key":"630_CR6","unstructured":"World Health Organization. COVID-19 Vaccines WHO EUL Issued. https:\/\/extranet.who.int\/pqweb\/vaccines\/vaccinescovid-19-vaccine-eul-issued (2022)."},{"key":"630_CR7","unstructured":"European Medicines Agency. Vaxzevria (Previously COVID-19 Vaccine AstraZeneca). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaxzevria-previously-covid-19-vaccine-astrazeneca (2022)."},{"key":"630_CR8","unstructured":"VIPER Group COVID19 Vaccine Tracker Team. COVID19 Vaccine Tracker. https:\/\/covid19.trackvaccines.org\/vaccines\/approved\/ (2022)."},{"key":"630_CR9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccin. Immunol. 17, 1055\u20131065 (2010).","journal-title":"Clin. Vaccin. Immunol."},{"key":"630_CR10","doi-asserted-by":"crossref","unstructured":"Plotkin S. A. & Gilbert P. B. Correlates of Protection in Plotkin\u2019s Vaccines 7th edn (eds Plotkin, S. A., Orenstein, W. A., Offit, P. A., Edwards, K. M.) Ch. 3 (Elsevier, 2018).","DOI":"10.1016\/B978-0-323-35761-6.00003-1"},{"key":"630_CR11","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/cis238","volume":"54","author":"SA Plotkin","year":"2012","unstructured":"Plotkin, S. A. & Gilbert, P. B. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 54, 1615\u20131617 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"630_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2034545","volume":"384","author":"SF Lumley","year":"2021","unstructured":"Lumley, S. F. et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N. Engl. J. Med. 384, 533\u201340. (2021).","journal-title":"N. Engl. J. Med."},{"key":"630_CR13","doi-asserted-by":"publisher","unstructured":"Addetia. A. et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J. Clin. Microbiol. https:\/\/doi.org\/10.1128\/JCM.02107-20 (2020).","DOI":"10.1128\/JCM.02107-20"},{"key":"630_CR14","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","volume":"590","author":"K McMahan","year":"2021","unstructured":"McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630\u2013634 (2021).","journal-title":"Nature"},{"key":"630_CR15","doi-asserted-by":"publisher","first-page":"eabj0299","DOI":"10.1126\/science.abj0299","volume":"373","author":"KS Corbett","year":"2021","unstructured":"Corbett, K. S. et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science 373, eabj0299 (2021).","journal-title":"Science"},{"key":"630_CR16","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1016\/j.cell.2021.05.040","volume":"184","author":"X He","year":"2021","unstructured":"He, X. et al. Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques. Cell 184, 3467\u201373.e11 (2021).","journal-title":"Cell"},{"key":"630_CR17","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","volume":"385","author":"MP O\u2019Brien","year":"2021","unstructured":"O\u2019Brien, M. P. et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N. Engl. J. Med. 385, 1184\u201395 (2021).","journal-title":"N. Engl. J. Med."},{"key":"630_CR18","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1056\/NEJMp2033538","volume":"384","author":"WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation.","year":"2021","unstructured":"WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation. et al. Placebo-controlled trials of Covid-19 vaccines\u2014why we still need them. N. Engl. J. Med. 384, e2 (2021).","journal-title":"N. Engl. J. Med."},{"key":"630_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.13091","volume":"310","author":"D Goldblatt","year":"2022","unstructured":"Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S. A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 310, 6\u201326 (2022).","journal-title":"Immunol. Rev."},{"key":"630_CR20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3201\/eid2902.221422","volume":"29","author":"DS Khoury","year":"2023","unstructured":"Khoury, D. S. et al. Correlates of protection, thresholds of protection, and immunobridging among persons with SARS-CoV-2 infection. Emerg. Infect. Dis. 29, 381\u2013388 (2023).","journal-title":"Emerg. Infect. Dis."},{"key":"630_CR21","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/s41591-021-01484-6","volume":"27","author":"RA Koup","year":"2021","unstructured":"Koup, R. A. et al. A government-led effort to identify correlates of protection for COVID-19 vaccines. Nat. Med. 27, 1493\u20131494 (2021).","journal-title":"Nat. Med."},{"key":"630_CR22","doi-asserted-by":"publisher","unstructured":"USG COVID-19 Response Team and Coronavirus Prevention Network (CoVPN) Biostatistics Team. USG COVID-19 Response Team and CoVPN Vaccine Efficacy Trial Immune correlates atatistical analysis plan. figshare https:\/\/doi.org\/10.6084\/m9.figshare.13198595.v13 (2022).","DOI":"10.6084\/m9.figshare.13198595.v13"},{"key":"630_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350 (2022).","journal-title":"Science"},{"key":"630_CR24","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/s41564-022-01262-1","volume":"7","author":"Y Fong","year":"2022","unstructured":"Fong, Y. et al. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. Nat. Microbiol. 7, 1996\u20132010 (2022).","journal-title":"Nat. Microbiol."},{"key":"630_CR25","unstructured":"Fong, Y. et al. Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial. Nat. Commun. 14, 331 (2023)."},{"key":"630_CR26","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032\u201340. (2021).","journal-title":"Nat. Med."},{"key":"630_CR27","unstructured":"Centers for Disease Control and Prevention. CDC Symptoms of Coronavirus. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/symptoms-testing\/symptoms.html (2021)."},{"key":"630_CR28","doi-asserted-by":"publisher","unstructured":"Gilbert P. B., Fong Y., Kenny A., Carone M. A controlled effects approach to assessing immune correlates of protection. Biostatistics https:\/\/doi.org\/10.1093\/biostatistics\/kxac24 (2022).","DOI":"10.1093\/biostatistics\/kxac24"},{"key":"630_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u201316. (2021).","journal-title":"N. Engl. J. Med."},{"key":"630_CR30","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187\u20132201 (2021).","journal-title":"N. Engl. J. Med."},{"key":"630_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2116185","volume":"386","author":"LM Dunkle","year":"2022","unstructured":"Dunkle, L. M. et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N. Engl. J. Med. 386, 531\u201343. (2022).","journal-title":"N. Engl. J. Med."},{"key":"630_CR32","unstructured":"National Institute for Biological Standards and Control (NIBSC). Instructions for Use of First WHO International Standard for anti-SARS-CoV-2 Immunoglobulin (Version 3.0, Dated 17\/12\/2020) NIBSC Code: 20\/136 https:\/\/www.nibsc.org\/science_and_research\/idd\/cfar\/covid-19_reagents.aspx (2021)."},{"key":"630_CR33","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(21)00527-4","volume":"397","author":"PA Kristiansen","year":"2021","unstructured":"Kristiansen, P. A. et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet 397, 1347\u20131348 (2021).","journal-title":"Lancet"},{"key":"630_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03154-6","volume":"11","author":"Y Huang","year":"2021","unstructured":"Huang, Y. et al. Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. Sci. Rep. 11, 23921 (2021).","journal-title":"Sci. Rep."},{"key":"630_CR35","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","volume":"3","author":"D Cromer","year":"2022","unstructured":"Cromer, D. et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe 3, e52\u2013e61 (2022).","journal-title":"Lancet Microbe"},{"key":"630_CR36","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"630_CR37","doi-asserted-by":"publisher","first-page":"e160565","DOI":"10.1172\/JCI160565","volume":"132","author":"ME Sobieszczyk","year":"2022","unstructured":"Sobieszczyk, M. E. et al. Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6\u2009months. J. Clin. Invest 132, e160565 (2022).","journal-title":"J. Clin. Invest"},{"key":"630_CR38","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1093\/bioinformatics\/bty407","volume":"34","author":"J Hadfield","year":"2018","unstructured":"Hadfield, J. et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics 34, 4121\u20134123 (2018).","journal-title":"Bioinformatics"},{"key":"630_CR39","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","volume":"185","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell 185, 2434\u20132451.e17 (2022).","journal-title":"Cell"},{"key":"630_CR40","doi-asserted-by":"publisher","first-page":"100405","DOI":"10.1016\/j.xcrm.2021.100405","volume":"2","author":"MJ Gorman","year":"2021","unstructured":"Gorman, M. J. et al. Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. Cell Rep. Med. 2, 100405 (2021).","journal-title":"Cell Rep. Med"},{"key":"630_CR41","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S2213-2600(22)00042-X","volume":"10","author":"BJ Wright","year":"2022","unstructured":"Wright, B. J. et al. Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study. Lancet Respir. Med. 10, 557\u201365. (2022).","journal-title":"Lancet Respir. Med"},{"key":"630_CR42","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","volume":"399","author":"DR Feikin","year":"2022","unstructured":"Feikin, D. R. et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 399, 924\u201344. (2022).","journal-title":"Lancet"},{"key":"630_CR43","doi-asserted-by":"publisher","first-page":"940562","DOI":"10.3389\/fimmu.2022.940562","volume":"13","author":"W Kulper-Schiek","year":"2022","unstructured":"Kulper-Schiek, W. et al. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review. Front Immunol. 13, 940562 (2022).","journal-title":"Front Immunol."},{"key":"630_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07418-y","volume":"22","author":"P Ssentongo","year":"2022","unstructured":"Ssentongo, P. et al. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. BMC Infect. Dis. 22, 439 (2022).","journal-title":"BMC Infect. Dis."},{"key":"630_CR45","doi-asserted-by":"publisher","unstructured":"Cromer, D. et al. Neutralising antibodies predict protection from severe COVID-19. medRxiv https:\/\/doi.org\/10.1101\/2022.06.09.22275942 (2022).","DOI":"10.1101\/2022.06.09.22275942"},{"key":"630_CR46","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","volume":"398","author":"APS Munro","year":"2021","unstructured":"Munro, A. P. S. et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 398, 2258\u201376. (2021).","journal-title":"Lancet"},{"key":"630_CR47","doi-asserted-by":"publisher","unstructured":"Liu, Y. M. et al. Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination. Infection https:\/\/doi.org\/10.1007\/s15010-022-01922-8 (2022).","DOI":"10.1007\/s15010-022-01922-8"},{"key":"630_CR48","doi-asserted-by":"crossref","unstructured":"Lumley T. Complex Surveys: A Guide to Analysis Using R Vol. 565 (John Wiley & Sons, 2010).","DOI":"10.1002\/9780470580066"},{"key":"630_CR49","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/. (2022)."},{"key":"630_CR50","doi-asserted-by":"publisher","unstructured":"van der Laan L., Zhang W., Gilbert P. B. Nonparametric estimation of the causal effect of a stochastic threshold-based intervention. Biometrics https:\/\/doi.org\/10.1111\/biom.13690 (2022).","DOI":"10.1111\/biom.13690"},{"key":"630_CR51","unstructured":"Westfall P. H., Young S. S. Resampling-Based Multiple Testing: Examples and Methods for P-Value Adjustment Vol. 279 (John Wiley & Sons, 1993)."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00630-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00630-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00630-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T23:36:38Z","timestamp":1678491398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00630-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["630"],"URL":"https:\/\/doi.org\/10.1038\/s41541-023-00630-0","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"9 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.J.K., I.H., S.S., A.M.S., J.M., and T.V. are employees of AstraZeneca and hold\/may hold stock in AstraZeneca.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}